Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Despite no strong evidence of clinical benefit, microdosing GLP-1s will likely continue as a strategy for some to profit off of the popular drug class.

During the industry’s onshoring rush of the last nine months, Eli Lilly has been among the most aggressive biopharma compa | Eli Lilly is allotting $3 billion to establish an oral medicines ...

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.